← Human Trials & Peer-Reviewed Studies
NMES Effects on Substrate Metabolism and IGF-1
Plain-language guide to NCT06850532: not phased randomized trial of IGF-1 LR3, 24 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06850532
- Phase
- not phased
- Status
- completed
- Start
- 2017-03-17
- Completion (planned or actual)
- 2019-02-13
- Participants
- 24 (actual)
- Design
- randomized, open label (everyone knows who gets what), screening
- Conditions studied
- The Effects of Neuromuscular Electrical Stimulation on Exercise Performance
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered not phased trial tested IGF-1 LR3.
The aim of this study is to investigate whether neuromuscular electrostimulation (NMES) training coupled with high-intensity interval training (HIIT) and moderate intensity continuous aerobic training has an effect on the metabolic, cardiovascular and hormonal components compared to respective training protocols without concurrent NMES as a exercise performance enhancement strategy.
It had three arms (groups): Assessment of baseline anthropometric, demographic and physiological components (experimental), Completion of MICT, MICT+NMES, HIIT, and HIIT+NMES protocols (experimental) and Assessment of post-test anthropometric, demographic and physiological components (experimental).
The registry classes the interventions as other.
Who Took Part
The registry lists 24 actual participants took part.
It was open to men only aged from 18 years up to 30 years.
Healthy volunteers could join, not only people with the condition.
The full record lists 0 inclusion and 1 exclusion criteria.
How the Study Was Run
The set-up was randomized, parallel-group and open-label.
The participants were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.
Groups ran in parallel: each of the participants stayed in one arm throughout.
Nothing was hidden in this open-label IGF-1 LR3 study: the participants and staff both knew the treatment.
It started in 2017-03-17 with completion listed for 2019-02-13.
It ran at 1 site in Turkey (Türkiye).
Its stated primary purpose is screening.
What Was Measured
Primary outcome: Body composition via Bioelectrical Impedance Analysis (Tanita 418-MA, Japan) (time frame: From enrollment to the end of treatment at 8 weeks). Heart rate (bpm) via 12-lead ECG (time frame: From enrollment to the end of treatment at 8 weeks). Blood Lactate Concentration (mmol/L) via Lactate Pro 2 analyzer (time frame: From enrollment to the end of treatment at 8 weeks).
What This Means in Plain Language
Put simply, this is a not phased, randomized trial of IGF-1 LR3 in 24 people.
Its size is small, so on its own it can only give an early look.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.